Usha Panchapakesan
Royal North Shore Hospital, St. Leonards
Sydney, NSW, Australia
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Organ protection beyond glycaemic control with SGLT2 inhibitors.
Journal: Nature reviews. Nephrology
Published: November 07, 2020
The primary cilia in diabetic kidney disease: A tubulocentric view?
Journal: The international journal of biochemistry & cell biology
Published: December 18, 2019
The role of toll-like receptors in diabetic kidney disease.
Journal: Current opinion in nephrology and hypertension
Published: October 24, 2017
Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Journal: Scientific reports
Published: July 09, 2016
Long non-coding RNAs-towards precision medicine in diabetic kidney disease?
Journal: Clinical science (London, England : 1979)
Published: April 03, 2016
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Journal: Scientific reports
Published: January 20, 2016
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.
Journal: PloS one
Published: September 24, 2015
The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.
Journal: Frontiers in immunology
Published: June 15, 2015
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Journal: Nephrology (Carlton, Vic.)
Published: March 10, 2015
Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.
Journal: PloS one
Published: February 26, 2015
Last Updated: 09/26/2026